XML 78 R62.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) |  | 1 Months Ended | 6 Months Ended
--- | --- | --- | ---
Mar. 17, 2021 | Sep. 30, 2020 | Jun. 30, 2021
Commitments And Contingencies [Line Items] |  |  |
Potential losses from claims, legal proceedings probable of occurring |  |  | $ 0
Maximum number of months before FDA can approve patent request |  | 30 months |
VUMERITY ANDA Litigation |  |  |
Commitments And Contingencies [Line Items] |  |  |
Maximum number of months before FDA can approve patent request | 30 months |  |

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | alks_CommitmentsAndContingenciesLineItems
Namespace Prefix: | alks_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum period before FDA can approve patent request. + References No definition available. + Details
Name: | alks_MaximumPeriodBeforeFDACanApprovePatentRequest
Namespace Prefix: | alks_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualProvision
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=alks_VUMERITYANDALitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |